Document is current

Article History

Received: 11 July 2025

Accepted: 26 October 2025

First Online: 3 December 2025

Change Date: 13 January 2026

Change Type: Update

Change Details: Supplementary Data was originally published with the incorrect title. The original article has been corrected.

Competing interests

: N.C.H.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. M.M.C.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. S.K.: No conflicts of interest. V.B.: Employee of Blueprint Medicines Corporation at the time of work. P.R.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. D.H.P.: No conflicts of interest. S.M.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. L.Y.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. R.W.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. F.W.: No conflicts of interest. L.L.: No conflicts of interest. N.F.: No conflicts of interest. C.A.B.: No conflicts of interest. T.A.Y.: Employee of University of Texas MD Anderson Cancer Center, where I am Vice President, Head of Clinical Development in the Therapeutics Discovery Division, which has a commercial interest in DDR and other inhibitors (IACS30380/ART0380 was licensed to Artios). Consultant for AbbVie, Acrivon, Adagene, Aduro, Almac, Amgen Inc., Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, BioCity Pharma, Blueprint Medicines Corporation, Boxer, BridGene Biosciences, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Debiopharm, Diffusion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, FoRx Therapeutics AG, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, Grey Wolf Therapeutics, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Joint Scientific Committee for Phase I Trials in Hong Kong, Kyn, Kyowa Kirin, Lumanity, MEI Pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey Therapeutics, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prelude Therapeutics, Prolynx, Protai Bio, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Thryv Therapeutics, Tolremo, Tome, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs and ZielBio. Grant/research support from Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, CPRIT, Cyteir, Department of Defense, Eli Lilly, EMD Serono, Exelixis, Forbius, F-Star, GlaxoSmithKline, Genentech, Gilead, Golfers Against Cancer, Haihe, Ideaya, ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, NIH/NCI, Pfizer, Pliant, Prelude, Ribon Therapeutics, Regeneron, Repare, Roche, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Synnovation, Tango, Tesaro, V Foundation, Vivace, Zenith and Zentalis. Stockholder in Seagen. K.K.: Funding from Apeiron, Blueprint Medicines Corporation, Repare, Schrodinger, and Novartis. J.R.M.: No conflicts of interest. S.R.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. M.L.R.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. L.M.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation. K.F.: Employee of Blueprint Medicines Corporation. Stockholder in Blueprint Medicines Corporation.